(19)
(11) EP 1 756 571 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.10.2010 Bulletin 2010/41

(45) Mention of the grant of the patent:
18.08.2010 Bulletin 2010/33

(21) Application number: 05776689.1

(22) Date of filing: 08.04.2005
(51) International Patent Classification (IPC): 
G01N 33/53(2006.01)
G01N 33/566(2006.01)
 G01N 33/564(2006.01)
G01N 33/567(2006.01)
(86) International application number:
PCT/US2005/011914
(87) International publication number:
WO 2005/108988 (17.11.2005 Gazette 2005/46)

(54)

REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS

VERFAHREN IN ECHTZEIT ZUR ERKENNUNG VON AKUTEN ENTZÜNDUNGSZUSTÄNDEN

PROCEDE EN TEMPS REEL DE DETECTION DE CONDITIONS INFLAMMATOIRES AIGUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 09.04.2004 US 560986 P
14.06.2004 US 579621 P

(43) Date of publication of application:
28.02.2007 Bulletin 2007/09

(60) Divisional application:
10005450.1 / 2216650

(73) Proprietor: University of Pittsburgh - Of the Commonwealth System of Higher Education
Pittsburgh, PA 15260 (US)

(72) Inventors:
  • AHEARN, Joseph M.
    Sewickley, Pennsylvania 15143 (US)
  • MANZI, Susan M.
    Wexford, Pennsylvania 15090 (US)

(74) Representative: Baldock, Sharon Claire et al
Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road
London WC1X 8BT
London WC1X 8BT (GB)


(56) References cited: : 
WO-A2-03/022223
   
  • LACH E ET AL: "Complement receptor 1 (CD35) on human reticulocytes" EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, vol. 14, no. 1, 1997, page 75, XP008089678 & 6TH EUROPEAN MEETING ON COMPLEMENT IN HUMAN DISEASE; INNSBRUCK, AUSTRIA; MARCH 12-15, 1997 ISSN: 0254-9670
  • MELICONI R ET AL: "COMPLEMENT ACTIVATION PRODUCTS IN IDIOPATHIC PULMONARY FIBROSIS RELEVANCE OF FRAGMENT BA TO DISEASE SEVERITY" CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, SAN DIEGO, CA, US, vol. 57, no. 1, 1990, pages 64-73, XP002445011 ISSN: 0090-1229
  • TSUBOI Y ET AL: "Increased concentration of C4d complement protein CSF in amyotrophic lateral sclerosis" JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY, vol. 57, 1994, pages 859-861, XP002961496 ISSN: 0022-3050
  • LACH-TRIFILIEFF ET AL: 'Complement Receptor 1 (CD35) on Human Reticulocytes: Normal Expression in Systemic Lupus Erythematosus and HIV-Infected Patients.' J IMMUNOL. vol. 162, no. 12, June 1999, pages 7549 - 7554, XP002993813
  • TAUSK F ET AL: 'The Expression of C3b Receptors in the Differentiation of Discoid Lupus Erythematosus and Systemic Lupus Erythematosus.' ARTHRITIS RHEUM. vol. 33, no. 6, June 1990, pages 888 - 892, XP002961495
  • YAMADA T ET AL: 'Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d.' NEUROSCI LETT. vol. 112, 1990, pages 161 - 166, XP002961494
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).